Navigation Links
Combining medication and psychosocial treatments may benefit patients with early-stage schizophrenia
Date:9/6/2010

Patients with early-stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapseand may have improved insight, quality of life and social functioningthan those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

Antipsychotic drugs are the mainstay of therapy for patients with schizophrenia, but long-term therapy is associated with adverse effects and poor adherence, according to background information in the article. "Most patients, even those with a good response to medication, continue to experience disabling residual symptoms, impaired social and occupational functioning and a high rate of relapse," the authors write. "Adding psychosocial treatment may produce greater improvements in functional outcome than does medication treatment alone."

Xiaofeng Guo, M.D., and Jinguo Zhai, M.D., of Second Xiangya Hospital, Central South University, Hunan, China, and colleagues evaluated this combination of therapies in 1,268 patients with early-stage schizophrenia treated from Jan. 1, 2005, through Oct. 31, 2007. A total of 633 were randomly assigned to receive pharmacotherapy plus a psychosocial intervention involving 48 one-hour group sessions. The intervention included four evidence-based practices: psychoeducation (instruction for families and caregivers about mental illness), family intervention (teaching coping and socializing skills), skills training and cognitive behavioral therapy. The other 635 patients received medication alone.

Rates of treatment discontinuation or change were 32.8 percent in the combined treatment group, compared with 46.8 percent in the medication-only group. The risk of relapse was lower among patients in the combination group, occurring in 14.6 percent of patients in that group and 22.5 percent of patients in the medication-only group.

The combined treatment group also exhibited greater improvements in insight, social functioning, activities of daily living and on four domains of quality of life, and a significantly higher proportion of them were employed or received education. There were no significant differences in either frequency or type of adverse events between the groups.

"Social outcomes reflect how patients live, function in society and perform their various roles (e.g., having a job, going to school or having friends)," the authors write. "Our study showed that a significantly higher proportion of patients receiving combined treatment obtained employment or accessed education. Thus, the findings support the results from previous studies that patients with schizophrenia receiving combined treatment had better outcomes. In particular, integrating a comprehensive therapy with medication treatment in patients with early-stage schizophrenia before the disease becomes chronic and disabling could improve long-term outcomes."


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Combining resistance and endurance training best for heart health
2. Gold Standard/Elsevier promotes medication safety and compliance via New MEDcounselor languages
3. Weight-Loss Surgery May Cut Type 2 Diabetes Medication Use
4. 1 in 4 stroke patients stop taking prevention medication within 3 months
5. EEG predicts response to medication for schizophrenia
6. Medications found to cause long term cognitive impairment of aging brain
7. Psychotropic medications can cause birth defects
8. Common Alzheimers medication helps skills necessary for safe driving
9. Non-IV-administered medication just as effective in stopping seizures
10. Publix Pharmacy Now Offers Pill Glide, an Innovative New Way for Children and Adults to Take Vitamins, Supplements and Medications
11. HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased to announce KLS Martin ... supporter of the event. , "We are pleased that KLS Martin is joining us ... ACPA President. "KLS Martin has a long track record of support of the American ...
(Date:2/23/2017)... ... ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North Hollywood ... of February, patients who visit Hamlin Dental Group will receive a ticket for a ... the Cheesecake Factory. , Tickets are available for routine dental visits and other ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... provider for the National Institute for Health and Care Excellence (NICE) ... in the National Health Service (NHS) to search, order and purchase medical and ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena ... 89052. Dr. Mahon was named a 2017 Top Patient Rated Henderson Dentist ... online directory that recognizes local physicians and dentists who have earned high ratings and ...
(Date:2/23/2017)... ... 2017 , ... ERT, a global data and technology company ... a leading clinical development service provider, has selected ERT’s Trial Oversight suite as ... part to an array of circumstances including the use of multiple data capture ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... China , 23. Februar 2017 Im ... , eine nationale Wirtschaftszone in der südwestlichen chinesischen Provinz Guizhou, ... der Errichtung einer Innovationsplattform aktiv an der Entwicklung einer eingebetteten ... Continue Reading ... ...
(Date:2/23/2017)... Research and Markets has announced the addition ... report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and ... global Fibromyalgia market. The research answers the following questions: ... Fibromyalgia and their clinical attributes? How are they positioned in the ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus Therapeutics ... discovery and development of innovative medicines targeting microRNAs, today ... 2016 financial results on Thursday, March 2, 2017 after ... conference call and webcast on March 2, 2017 at ... full year 2016 financial results and provide a general ...
Breaking Medicine Technology: